Abstract
The p38 mitogen activated protein (MAP) kinase is an integral enzyme involved in the production of a wide variety of pro-inflammatory cytokines from various cell types. The identification of this kinase and of the diaryl imidazole containing inhibitor, SB203580, initiated an intense discovery effort in this field. Numerous inhibitors were subsequently produced containing replacements for the imidazole, as well as some of the pharmacophores attached to it. During this time many other classes of potent p38 inhibitors emerged containing scaffolds and binding components not found in the diaryl imidazole group. This review summarizes nine of those classes. At least one of these classes requires the kinase to undergo reorganization prior to binding. From this diverse set of inhibitors four compounds have been reported advancing into human clinical trials.
Keywords: kinase inhibition, anti-cancer agents, purine-derived compounds, cell cycle, solid phase synthesis, biological activity
Current Topics in Medicinal Chemistry
Title: The Non-Diaryl Heterocycle Classes of p38 MAP Kinase Inhibitors
Volume: 2 Issue: 9
Author(s): Pier F. Cirillo, Christopher Pargellis and John Regan
Affiliation:
Keywords: kinase inhibition, anti-cancer agents, purine-derived compounds, cell cycle, solid phase synthesis, biological activity
Abstract: The p38 mitogen activated protein (MAP) kinase is an integral enzyme involved in the production of a wide variety of pro-inflammatory cytokines from various cell types. The identification of this kinase and of the diaryl imidazole containing inhibitor, SB203580, initiated an intense discovery effort in this field. Numerous inhibitors were subsequently produced containing replacements for the imidazole, as well as some of the pharmacophores attached to it. During this time many other classes of potent p38 inhibitors emerged containing scaffolds and binding components not found in the diaryl imidazole group. This review summarizes nine of those classes. At least one of these classes requires the kinase to undergo reorganization prior to binding. From this diverse set of inhibitors four compounds have been reported advancing into human clinical trials.
Export Options
About this article
Cite this article as:
Cirillo F. Pier, Pargellis Christopher and Regan John, The Non-Diaryl Heterocycle Classes of p38 MAP Kinase Inhibitors, Current Topics in Medicinal Chemistry 2002; 2 (9) . https://dx.doi.org/10.2174/1568026023393390
DOI https://dx.doi.org/10.2174/1568026023393390 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cocaine and Acute Vascular Diseases
Current Drug Abuse Reviews Targeting Transcription Factors for Cancer Gene Therapy
Current Gene Therapy VEGF and Colon Cancer Growth Beyond Angiogenesis: Does VEGF Directly Mediate Colon Cancer Growth Via a Non-angiogenic Mechanism?
Current Pharmaceutical Design Intestinal Immunomodulation. Role of Regulative Peptides and Promising Pharmacological Activities
Current Pharmaceutical Design Effect of Simvastatin use on Autonomic Function in Patients with End Stage Renal Disease
Cardiovascular & Hematological Disorders-Drug Targets Immunomodulatory and Anti-Viral Activities of Pertussis Toxin and of Its Non-Toxic Derivatives
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Allosteric Inhibition of G-Protein Coupled Receptor Oligomerization: Strategies and Challenges for Drug Development
Current Topics in Medicinal Chemistry Hypercortisolemia and Glucocorticoid Receptor-Signaling Insufficiency in Alzheimer’ s Disease Initiation and Development
Current Alzheimer Research The Promise of Slow Down Ageing May Come from Curcumin
Current Pharmaceutical Design Clinical Management of Oral Lichen Planus: A Systematic Review
Mini-Reviews in Medicinal Chemistry The Immune System, Involvement in Neurodegenerative Diseases, Ageing and Cancer
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents A New Approach to the Inflammatory/Autoimmune Diseases
Recent Patents on Anti-Infective Drug Discovery Regulation of Myocardial Extracellular Matrix Dynamic Changes in Myocardial Infarction and Postinfarct Remodeling
Current Cardiology Reviews The Design and Development of Deferiprone (L1) and Other Iron Chelators for Clinical Use: Targeting Methods and Application Prospects
Current Medicinal Chemistry A Brief Review of the Computational Identification of Antifreeze Protein
Current Organic Chemistry Role of Novel Drug Delivery Systems in Coronavirus Disease-2019 (COVID-19): Time to Act Now
Current Drug Delivery Non Pregnant Human Uterus as Source of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Prognostic Impact of Red Cell Distribution Width on the Development of Contrast-Induced Nephropathy, Major Adverse Cardiac Events, and Mortality in Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention
Current Cardiology Reviews <i>In silico</i> Analysis of <i>Plasmodium falciparum</i> Actin and Profilin Interaction at the Interface Region for Antimalarial Drug Designing
Letters in Drug Design & Discovery A Water-Soluble Fenbendazole (FBZ) Formulation for Treating Pinworm Infections in Laboratory Animals
Drug Delivery Letters